Skali, H., Parving, H. H, Parfrey, P., Burdmann, E. A, Lewis, E. F, Ivanovich, P., Keithi-Reddy, S. R, McGill, J. B, McMurray, J., Singh, A. K, Solomon, S., Uno, H. & Pfeffer, MA. (2011). Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: The trial to reduce cardiovascular events with aranesp therapy (TREAT) experience. Circulation,124(25), 2903-2908. United States: Lippincott Williams & Wilkins. Retrieved from https://doi.org/10.1161/CIRCULATIONAHA.111.030411
More strokes were observed in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) among patients assigned to darbepoetin alfa. We sought to identify baseline characteristics and postrandomization factors that might explain this association.
Mary MacKillop Institute for Health Research
Access may be restricted.